ED90 of Teglidine for Suppressing LMA Insertion Response in the Elderly

NANot yet recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

June 1, 2027

Study Completion Date

June 30, 2027

Conditions
Urological Surgery
Interventions
DRUG

Taiglididine

The first patient receives an intravenous injection of 1 mg taiglididine for anesthesia induction, followed by 1-2 mg/kg propofol. When the patient's bispectral index (BIS) drops below 60, eyelash reflex disappears, and MOAA/S score is 0, intravenous rocuronium 0.6 mg/kg is given, and a laryngeal mask is inserted by a senior anesthesiologist using a unified method 1 min later. From the second patient onward, the taiglididine dose is dynamically adjusted based on the previous patient's response to laryngeal mask insertion using BCD-UDM: if the previous patient shows a positive insertion response (positive response or MOAA/S ≥2 within 2 min after induction), the next patient's dose increases by 0.1 mg; if negative, a random number (1-95) generated by computer determines the dose: doses remain unchanged when the number is 6-95 (89% probability) and decrease by 0.1 mg when the number is 1-5 (11% probability). A collaborator not involved in result evaluation provides a sealed envelope with

All Listed Sponsors
lead

The First People's Hospital of Lianyungang

OTHER

NCT07096115 - ED90 of Teglidine for Suppressing LMA Insertion Response in the Elderly | Biotech Hunter | Biotech Hunter